Nektar Therapeutics Financial Statements (NKTR)
|
|
|
|
Report date
|
|
|
01.03.2022 |
28.02.2023 |
05.03.2024 |
14.03.2025 |
13.03.2026 |
|
08.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
101.9 |
92.1 |
90.1 |
98.4 |
55.2 |
|
55.6 |
|
Operating Income, bln rub |
|
|
-446.1 |
-240.2 |
-137.4 |
-105.2 |
-130.8 |
|
-125.1 |
|
EBITDA, bln rub |
? |
|
-461.8 |
-323.9 |
-243.1 |
-86.7 |
-129.7 |
|
-120.1 |
|
Net profit, bln rub |
? |
|
-523.8 |
-368.2 |
-276.1 |
-119.0 |
-164.1 |
|
-158.1 |
|
|
OCF, bln rub |
? |
|
-412.7 |
-304.0 |
-192.6 |
-175.7 |
-208.5 |
|
-203.8 |
|
CAPEX, bln rub |
? |
|
15.0 |
5.68 |
0.865 |
1.47 |
0.171 |
|
0.187 |
|
FCF, bln rub |
? |
|
-427.6 |
-309.7 |
-193.5 |
-177.2 |
-208.7 |
|
-203.9 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
|
|
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
523.1 |
310.7 |
190.9 |
172.9 |
186.0 |
|
180.4 |
|
Cost of production, bln rub |
|
|
24.9 |
21.6 |
36.6 |
30.7 |
0.000 |
|
0.347 |
|
R&D, bln rub |
|
|
400.3 |
218.3 |
114.2 |
120.9 |
117.3 |
|
122.5 |
|
Interest expenses, bln rub |
|
|
47.3 |
28.9 |
25.3 |
28.1 |
26.2 |
|
29.2 |
|
|
Assets, bln rub |
|
|
1 117 |
710.6 |
398.0 |
303.9 |
280.4 |
|
763.3 |
|
Net Assets, bln rub |
? |
|
679.5 |
366.6 |
131.0 |
60.7 |
89.8 |
|
576.2 |
|
Debt, bln rub |
|
|
143.2 |
131.5 |
117.8 |
102.6 |
148.9 |
|
143.4 |
|
Cash, bln rub |
|
|
734.0 |
505.0 |
303.6 |
255.2 |
245.8 |
|
568.6 |
|
Net debt, bln rub |
|
|
-590.8 |
-373.5 |
-185.8 |
-152.7 |
-96.8 |
|
-425.2 |
|
|
Ordinary share price, rub |
|
|
202.7 |
|
|
14.0 |
42.3 |
|
65.5 |
|
Number of ordinary shares, mln |
|
|
12.2 |
12.5 |
12.7 |
13.7 |
16.9 |
|
24.7 |
|
|
Market cap, bln rub |
|
|
2 476 |
0 |
0 |
191 |
713 |
|
1 621 |
|
EV, bln rub |
? |
|
1 886 |
-373 |
-186 |
39 |
616 |
|
1 196 |
|
Book value, bln rub |
|
|
603 |
290 |
131 |
61 |
90 |
|
576 |
|
|
EPS, rub |
? |
|
-42.9 |
-29.5 |
-21.8 |
-8.68 |
-9.73 |
|
-6.39 |
|
FCF/share, rub |
|
|
-35.0 |
-24.8 |
-15.3 |
-12.9 |
-12.4 |
|
-8.24 |
|
BV/share, rub |
|
|
49.3 |
23.3 |
10.3 |
4.43 |
5.32 |
|
23.3 |
|
|
EBITDA margin, % |
? |
|
-453.2% |
-351.8% |
-269.8% |
-88.1% |
-234.9% |
|
-215.9% |
|
Net margin, % |
? |
|
-514.0% |
-400.0% |
-306.3% |
-120.9% |
-297.1% |
|
-284.2% |
|
FCF yield, % |
? |
|
-17.3% |
|
|
-92.6% |
-29.3% |
|
-12.6% |
|
ROE, % |
? |
|
-77.1% |
-100.4% |
-210.8% |
-195.9% |
-182.6% |
|
-27.4% |
|
ROA, % |
? |
|
-46.9% |
-51.8% |
-69.4% |
-39.2% |
-58.5% |
|
-20.7% |
|
|
P/E |
? |
|
-4.73 |
0.00 |
0.00 |
-1.61 |
-4.35 |
|
-10.3 |
|
P/FCF |
|
|
-5.79 |
0.00 |
0.00 |
-1.08 |
-3.42 |
|
-7.95 |
|
P/S |
? |
|
24.3 |
0.00 |
0.00 |
1.94 |
12.9 |
|
29.1 |
|
P/BV |
? |
|
4.11 |
0.00 |
0.00 |
3.15 |
7.94 |
|
2.81 |
|
EV/EBITDA |
? |
|
-4.08 |
1.15 |
0.76 |
-0.45 |
-4.75 |
|
-9.96 |
|
Debt/EBITDA |
|
|
1.28 |
1.15 |
0.76 |
1.76 |
0.75 |
|
3.54 |
|
|
R&D/CAPEX, % |
|
|
2 670% |
3 846% |
13 198% |
8 236% |
68 614% |
|
65 524% |
|
|
CAPEX/Revenue, % |
|
|
14.7% |
6.17% |
0.96% |
1.49% |
0.31% |
|
0.34% |
|
| Nektar Therapeutics shareholders |
